Drug combination delivered by nanoparticles may help in melanoma treatment
- Details
- Category: Research
The first of a new class of medication that delivers a combination of drugs by nanoparticle may keep melanoma from becoming resistant to treatment, according to Penn State College of Medicine researchers. CelePlum-777 combines a special ratio of the drugs Celecoxib, an anti-inflammatory, and Plumbagin, a toxin. With the drug, the cells have difficulty overcoming the effect of having more than one active ingredient.
Cooking at home tonight? It's likely cheaper and healthier, study finds
- Details
- Category: Research
Researchers from the University of Washington School of Public Health have been peeking into kitchens - via interviews - for years now. They've just published results showing people who cook at home more often are likely to eat a healthier overall diet. The measurement used to define a healthy diet is called the Healthy Eating Index. It gauges whether a person's diet is giving them the right combination of fruits, vegetables and other elements.
Phage therapy shown to kill drug-resistant superbug
- Details
- Category: Research
Scientists from the University of Liverpool have shown that phage therapy could offer a safe and effective alternative to antibiotics in the treatment of Cystic Fibrosis lung infections. Chronic lung infections caused by the bacterium Pseudomonas aeruginosa are becoming increasingly difficult to treat due to antimicrobial resistance (AMR). With limited alternative therapeutic options available this has led to a renewed interest in (bacterio)phage therapy.
New England Journal of Medicine publishes long-term results of Gleevec®
- Details
- Category: Research
In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic myeloid leukemia, or CML. The New England Journal of Medicine has published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent.
Researchers identify a new way to promote tissue regeneration
- Details
- Category: Research
Houston Methodist researchers have identified an immune pathway that promotes the formation of a cell that can develop into new tissues and organs. In a new study published in the journal Stem Cells, a team led by John P. Cooke, M.D., Ph.D., chair of Cardiovascular Sciences, Houston Methodist Research Institute, described how activation of innate immunity enhances nuclear reprogramming, one of the first steps in tissue regeneration, or the formation of new tissues and organs from a single cell in the body.
Potential drug candidates halt prostate and breast cancer growth
- Details
- Category: Research
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers. The new research, published recently as two separate studies in ACS Central Science and the Journal of the American Chemical Society, demonstrates that a new class of drugs called small molecule RNA inhibitors can successfully target and kill specific types of cancer.
Antioxidants and lung cancer risk
- Details
- Category: Research
An epidemiological study published in Frontiers in Oncology suggests that a diet high in carotenoids and vitamin C may protect against lung cancer. The study authors found that vitamin C appears to reduce the risk of lung cancer in heavy smokers while beta-carotene, alpha-carotene, beta-cryptoxanthin, and lycopene play the same role in male heavy smokers.
More Pharma News ...
- Sulforaphane, a phytochemical in broccoli sprouts, ameliorates obesity
- How molecular machines may drive the future of disease detection and drug delivery
- Volkswagen's excess emissions will lead to 1,200 premature deaths in Europe
- Scientists stimulate immune system, stop cancer growth
- Inhaler users get about half as much medicine as they should from each puff
- Molecule stops fatal pediatric brain tumor
- Alzheimer's drug prescribed off-label could pose risk for some